Cooperation for Better Treatment of Polypharmacy in the Community
Status
Conditions
Treatments
Details and patient eligibility
About
The elderly population today relies heavily on medication consumption. While there are cases where using multiple medications is necessary and reasonable, it also increases the risk of inappropriate treatment and adverse drug effects. This randomized, controlled trial aims to examine the effectiveness of incorporating drug reviews as an integral part of clinical practice for older patients admitted to a Municipal in-patient acute care (MipAC) unit in Oslo, Norway. The intervention involves a clinical drug review conducted by a MipAC physician under the guidance of a geriatrician, followed by a telephone consultation between the MipAC physician and the patient's family physician (FP). The primary outcome measure is health-related quality of life, while secondary outcome measures include physical and cognitive function, dry mouth, hospital admissions, and survival. The environmental impact of the study intervention will also be assessed and compared to usual care.
Full description
The aim of this study is to evaluate the effect of collaborative drug reviews by MipAC physicians, supervised by geriatricians, and FPs on clinically relevant outcome measures in the MipAC patient population aged 70+. The investigators will also assess the environmental impact of the study intervention and compare it to usual care.
The study is a randomized, single-blind, controlled trial with 16 weeks follow-up. In addition, we plan to acquire registry data on MipAC readmissions, hospital admissions, and mortality after one year.
The investigators will recruit 1-4 MipAC physicians to take part in the study. The project physicians will be responsible for the patient's general medical treatment, but will also perform a structured, clinical drug review that goes beyond what is considered usual care. The project physicians will provide necessary information on the patient's medical history and drug use from the medical records, carry out a medical history from the patient, and a physical examination. Relevant blood analyses and other supplementary tests will be ordered if not already available. The clinical drug review will be aimed at evaluating whether current medications are indicated, whether the patient's medical conditions are satisfactorily compensated, whether dosages are appropriate, whether the patient has adverse drug effects, and whether drug-drug or drug-disease interactions are present or likely to occur. The investigators will develop a structured framework for the drug reviews, and the MipAC physicians will receive clinical supervision from a consultant in geriatric medicine.
After performing the clinical drug review, the MipAC physician will offer the patient's FP a telephone based or digital meeting with the purpose of combining the assessments of the MipAC physician and the competence of the FP in a common drug review. The two physicians will review the patient's drug list systematically and discuss if any adjustments should be done, as well as the patient's need for further follow-up.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age 70+
- Admitted to the MipAC unit
- Use of at least six different systemic medications taken regularly
- Informed consent by the patient
Exclusion criteria
- Previously included in the study
- Not speaking or understanding Norwegian
- Residing outside of the municipality of Oslo
- Planned discharge within 24 hours
- Isolated for infection control reasons
- Considered too ill to approach or life expectancy judged to be less than six months
- Personnel at the MipAC unit discourage participation (in case of important reasons not covered by the other exclusion criteria)
Trial design
Primary purpose
Allocation
Interventional model
Masking
139 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Rita Romskaug, MD, PhD; Leonor R Santervas, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal